Latest News

 Filter by Provider

Outback's value push and a franchisee bankruptcy shape the turnaround story.

Debt paydown hit target leverage as Koch Filter lifted sales and guidance.

Debt-for-equity swap and $400 million in new capital reshape Mercer's balance sheet.

Record quarterly profits lifted by ice-class fleet and a new $145 million loan.

What happened? Shares of cosmetics company e.l.f. Beauty (NYSE:ELF) jumped 8.5% in the afternoon session after the company reported second-quarter fiscal 202...

What happened? Shares of internet, cable TV, and phone provider Cable One (NYSE:CABO) fell 14.4% in the afternoon session after the company reported third-qu...

What happened? Shares of energy drink company Monster Beverage (NASDAQ:MNST) fell 2.7% in the afternoon session after the company reported third-quarter resu...

What happened? Shares of insurance data analytics provider Verisk Analytics (NASDAQ:VRSK) fell 3.7% in the afternoon session after the company reported third...

Management is pivoting to commerce and video as search referrals decline.

Occupancy climbed sharply, but the strategic sale review has slowed.

The U.S. hasn't had a real recession since the Great Recession of 2008.

Leverage goal hit early as production set records and assets fund their own growth.

Joint venture yields rose as originations held steady in a slower market.

Cote's cost decline and a royalty buyback reshape the cash flow outlook.

Cathie Wood's firm ARK Invest bought and sold $437 million worth of stock on Thursday as tech names like Nvidia, Google and SpaceX plummeted.

Summer occupancy shortfall prompted a lowered full-year outlook.

Elanco beat expectations and raised guidance on strong innovation sales.

Record backlog and rising semiconductor demand, but lead times are stretching.

Galileo's early market share and a new debt paydown plan shape the quarter's story.

Management details a CLO refinancing and a leverage reduction plan.

Record retail sales came alongside a sharp drop in alternative investment returns.

Legacy reserve risk is being handed off as the company reshapes its specialty focus.

Shorter-duration structured finance deals are reshaping the insurer's business mix.

NerdWallet's sales grew in Q3. Its costs just rose a whole lot more.

Micron is bouncing back after Thursday’s chip rout, but the reason it fell- a possible slowdown in data center construction- hasn’t gone away.

Predictable subscription cash flows underpin a new $60 million special dividend.

Digital growth outpaced the core as full-year guidance moved higher.

Management eyes nonaccrual resolutions and office exits to redeploy capital

Some companies will perform pretty well regardless of whether or not interest rates rise.

Opendoor is selling more and buying a lot more homes, but margins are shrinking, losses are widening, and its year-end profit goal is now behind schedule.

Taiwan Semiconductor is a top option in the AI investment space.

European expansion and Canadian brand strength drove a record quarter.

Management details its data center power push and expanding Cedar LNG progress.

Midweek business travel and margin gains lifted results, prompting higher guidance.

Production jumped 20% as Baobab resumed and free cash flow nears.

Record quarterly EBITDA is paired with a major asset sale and a new acquisition.

There's a big factor you need to address.

Oklo’s stock is jumping after earnings, but the company is basically pre-revenue, and its first plant is still years from coming online.

Humana's Star rating gains and new BlackRock partnership shape its 2027 margin outlook.

Wholesale gains offset softer retail fuel volumes in a strong quarter.

Capital recycling and AI expansion drove a 10% funds-from-operations gain.

Record cash flow offset by rising input costs and a sharply lower outlook

At 67, you've hit full retirement age--here's what the typical monthly check looks like.

Lift truck and material handling solutions manufacturer Hyster-Yale Materials Handling (NYSE:HY) fell short of the market’s revenue expectations in Q3 2026, ...

Nine-month capital spending hit $412.8 million on the way to its annual goal.

Leadership changed hands as Concentra weighs entry into a new state.

REGENXBIO (NASDAQ:RGNX) is approaching pivotal trial results for its eye disease gene therapy and preparing a U.S. application for its Duchenne muscular dystrophy treatment, executives said during the company’s third-quarter earnings call. The company and partner AbbVie expect top-line results this